首页 > 最新文献

Hepatic Medicine : Evidence and Research最新文献

英文 中文
Chimeric Livers: Interspecies Blastocyst Complementation and Xenotransplantation for End-Stage Liver Disease. 嵌合肝脏:种间囊胚补体和异种移植治疗终末期肝病。
IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-02-16 eCollection Date: 2024-01-01 DOI: 10.2147/HMER.S440697
Madelyn J Blake, Clifford J Steer

Orthotopic liver transplantation (OLT) currently serves as the sole definitive treatment for thousands of patients suffering from end-stage liver disease; and the existing supply of donor livers for OLT is drastically outpaced by the increasing demand. To alleviate this significant gap in treatment, several experimental approaches have been devised with the aim of either offering interim support to patients waiting on the transplant list or bioengineering complete livers for OLT by infusing them with fresh hepatic cells. Recently, interspecies blastocyst complementation has emerged as a promising method for generating complete organs in utero over a short timeframe. When coupled with gene editing technology, it has brought about a potentially revolutionary transformation in regenerative medicine. Blastocyst complementation harbors notable potential for generating complete human livers in large animals, which could be used for xenotransplantation in humans, addressing the scarcity of livers for OLT. Nevertheless, substantial experimental and ethical challenges still need to be overcome to produce human livers in larger domestic animals like pigs. This review compiles the current understanding of interspecies blastocyst complementation and outlines future possibilities for liver xenotransplantation in humans.

目前,异位肝移植(OLT)是成千上万终末期肝病患者唯一的最终治疗方法;而用于异位肝移植的现有供体肝脏的供应量远远超过了日益增长的需求。为了缓解治疗方面的这一重大缺口,人们设计了几种实验方法,目的是为等待移植名单上的患者提供临时支持,或者通过注入新鲜肝细胞,对完整肝脏进行生物工程改造,以进行 OLT。最近,种间囊胚互补已成为在短时间内在子宫内生成完整器官的一种有前途的方法。这种方法与基因编辑技术相结合,为再生医学带来了潜在的革命性变革。囊胚补体具有在大型动物体内生成完整人类肝脏的显著潜力,可用于人类的异种移植,从而解决用于有组织移植的肝脏稀缺的问题。然而,要在猪等大型家畜体内产生人类肝脏,仍需克服大量的实验和伦理挑战。这篇综述汇编了目前对种间囊胚互补的理解,并概述了人类肝脏异种移植的未来可能性。
{"title":"Chimeric Livers: Interspecies Blastocyst Complementation and Xenotransplantation for End-Stage Liver Disease.","authors":"Madelyn J Blake, Clifford J Steer","doi":"10.2147/HMER.S440697","DOIUrl":"10.2147/HMER.S440697","url":null,"abstract":"<p><p>Orthotopic liver transplantation (OLT) currently serves as the sole definitive treatment for thousands of patients suffering from end-stage liver disease; and the existing supply of donor livers for OLT is drastically outpaced by the increasing demand. To alleviate this significant gap in treatment, several experimental approaches have been devised with the aim of either offering interim support to patients waiting on the transplant list or bioengineering complete livers for OLT by infusing them with fresh hepatic cells. Recently, interspecies blastocyst complementation has emerged as a promising method for generating complete organs in utero over a short timeframe. When coupled with gene editing technology, it has brought about a potentially revolutionary transformation in regenerative medicine. Blastocyst complementation harbors notable potential for generating complete human livers in large animals, which could be used for xenotransplantation in humans, addressing the scarcity of livers for OLT. Nevertheless, substantial experimental and ethical challenges still need to be overcome to produce human livers in larger domestic animals like pigs. This review compiles the current understanding of interspecies blastocyst complementation and outlines future possibilities for liver xenotransplantation in humans.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"16 ","pages":"11-29"},"PeriodicalIF":2.6,"publicationDate":"2024-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10878318/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139912491","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Free Triiodothyronine, Gamma-Glutamyl Transpeptidase and Spontaneous Bacterial Peritonitis Index: A Novel Model for Predicting 1-Year Mortality in Patients with HBV-Related Hepatic Encephalopathy. 游离三碘甲状腺原氨酸、γ-谷氨酰转肽酶和自发性细菌性腹膜炎指数:预测 HBV 相关肝性脑病患者 1 年死亡率的新模型。
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-22 eCollection Date: 2024-01-01 DOI: 10.2147/HMER.S450638
Lin Lin, Ze-Yu Huang, Kai Liu, Xue-Cheng Tong, Zhi-Xin Zhang, Yuan Xue

Background and aims: Hepatic encephalopathy (HE) is characterized by neuropsychiatric manifestations in patients with decompensated cirrhosis (DC) and/or liver failure. This study aimed to investigate the predictive value of thyroid hormone in patients with HE.

Methods: Patients with DC and HE were enrolled, and multivariate logistic analysis was conducted to analyze the risk factors for 1-year mortality.

Results: Among the 81 patients with HBV-related DC and HE, 9 (11.1%) died within 3 months, and 15 (18.5%) died within the first year. More patients with FT3 < 3.5pmol/L had ascites (33.3% vs 8.9%, P<0.01) and higher model for end-stage liver disease (MELD) (Z=3.669, P<0.01). Additionally, free triiodothyronine (FT3) levels were lower in the non-survivor group (P<0.01). FT3 exhibited a negative correlation with international normalized ratio and MELD (both P<0.05). Multivariate analysis revealed that FT3, gamma-glutamyl transpeptidase (GGT), and spontaneous bacterial peritonitis (SBP) were independent risk factors for 1-year mortality of HE. A new model incorporating FT3, GTT, and SBP demonstrated superiority to MELD based on the AUROC (0.9 and 0.752, P=0.04).

Conclusion: Low FT3, but not thyroid-stimulating hormone and free tetraiodothyronine, was identified as an independent risk factor for 1-year mortality in patients with DC and HE. The newly proposed prognostic model, which includes FT3, GTT, and SBP, holds significant predictive value.

背景和目的:肝性脑病(HE)的特征是失代偿性肝硬化(DC)和/或肝衰竭患者的神经精神表现。本研究旨在探讨甲状腺激素对 HE 患者的预测价值:方法:纳入DC和HE患者,进行多变量逻辑分析,分析1年死亡率的风险因素:在81例HBV相关DC和HE患者中,9例(11.1%)在3个月内死亡,15例(18.5%)在1年内死亡。更多FT3<3.5pmol/L的患者出现腹水(33.3%对8.9%,PC结论:低FT3,而非促甲状腺激素和游离四碘甲状腺原氨酸,被确定为DC和HE患者1年死亡率的独立危险因素。新提出的预后模型包括 FT3、GTT 和 SBP,具有重要的预测价值。
{"title":"The Free Triiodothyronine, Gamma-Glutamyl Transpeptidase and Spontaneous Bacterial Peritonitis Index: A Novel Model for Predicting 1-Year Mortality in Patients with HBV-Related Hepatic Encephalopathy.","authors":"Lin Lin, Ze-Yu Huang, Kai Liu, Xue-Cheng Tong, Zhi-Xin Zhang, Yuan Xue","doi":"10.2147/HMER.S450638","DOIUrl":"10.2147/HMER.S450638","url":null,"abstract":"<p><strong>Background and aims: </strong>Hepatic encephalopathy (HE) is characterized by neuropsychiatric manifestations in patients with decompensated cirrhosis (DC) and/or liver failure. This study aimed to investigate the predictive value of thyroid hormone in patients with HE.</p><p><strong>Methods: </strong>Patients with DC and HE were enrolled, and multivariate logistic analysis was conducted to analyze the risk factors for 1-year mortality.</p><p><strong>Results: </strong>Among the 81 patients with HBV-related DC and HE, 9 (11.1%) died within 3 months, and 15 (18.5%) died within the first year. More patients with FT3 < 3.5pmol/L had ascites (33.3% vs 8.9%, P<0.01) and higher model for end-stage liver disease (MELD) (Z=3.669, P<0.01). Additionally, free triiodothyronine (FT3) levels were lower in the non-survivor group (P<0.01). FT3 exhibited a negative correlation with international normalized ratio and MELD (both P<0.05). Multivariate analysis revealed that FT3, gamma-glutamyl transpeptidase (GGT), and spontaneous bacterial peritonitis (SBP) were independent risk factors for 1-year mortality of HE. A new model incorporating FT3, GTT, and SBP demonstrated superiority to MELD based on the AUROC (0.9 and 0.752, P=0.04).</p><p><strong>Conclusion: </strong>Low FT3, but not thyroid-stimulating hormone and free tetraiodothyronine, was identified as an independent risk factor for 1-year mortality in patients with DC and HE. The newly proposed prognostic model, which includes FT3, GTT, and SBP, holds significant predictive value.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"16 ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2024-01-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10819082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139569902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicinal Plants in Treating Hepatitis B Among Communities of Central Region of Ethiopia. 埃塞俄比亚中部地区社区治疗乙型肝炎的药用植物。
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-29 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S440351
Gizachew Beykaso, Tilahun Teklehaymanot, Andargachew Mulu, Nega Berhe, Dawit Hailu Alemayehu, Mirutse Giday

Purpose: In Ethiopia, most people rely heavily on traditional therapeutic plants that have been used for years. The practice of traditional medicines use to treat hepatitis is currently gaining popularity due to the limited availability and affordability of modern drugs. The aim of this study was, therefore, to assess the traditional medicinal plants use to treat viral hepatitis among communities of Central region of Ethiopia.

Methods: Data was collected from November 2018 to December 2021 in Central Ethiopia. An open-ended semi-structured interview was used among purposively selected herbalists, traditional medicine entrepreneurs, village heads, and patients visiting traditional healers for hepatitis treatments. A 5 mL blood sample was collected from patients who visited a traditional healers' clinic for hepatitis treatment and tested for HBsAg and HCV-antibody by using ELISA. Among HBsAg-positives, further nucleic acid test for HBV-DNA load was assessed to measure the effects of prescribed medicinal plants.

Results: Herbalists cited 24 plants that were used for hepatitis treatment; of which Rumex nepalensis, Vangueria apiculata, and Solanum incanum were the most frequently cited plants. Remedies were commonly prepared by crushing or powdering, mixing them with water, and taken orally. Forty-two individuals were diagnosed and treated as hepatitis patients by herbalists, of which eight of them were HBsAg-positive but no positives for anti-HCV ELISA. At the third and sixth months of viral load assessment among HBsAg-positive, serum HBV-DNA suppression was observed in three individuals treated with different combinations of frequently cited plants.

Conclusion: In this study, traditional healers used various plants to treat hepatitis. HBV-DNA suppressive activity was detected in three NAT-positive individuals who were treated by using a mixture of these frequently cited and highest preference-ranked plants. This suggests that these plants have antiviral properties and serve as a basis for more pharmacological research in the quest for new antiviral agents.

目的:在埃塞俄比亚,大多数人严重依赖使用多年的传统治疗植物。由于现代药物供应有限且价格低廉,使用传统药物治疗肝炎的做法目前正日益流行。因此,本研究旨在评估埃塞俄比亚中部地区社区使用传统药用植物治疗病毒性肝炎的情况:数据收集时间为 2018 年 11 月至 2021 年 12 月。在有目的性地选择的草药医生、传统医药企业家、村长和前往传统医治者处治疗肝炎的患者中采用了开放式半结构访谈。从前往传统疗法诊所接受肝炎治疗的患者身上采集了 5 mL 血液样本,并使用 ELISA 方法检测了 HBsAg 和 HCV 抗体。在 HBsAg 阳性患者中,进一步进行了 HBV DNA 负载核酸检测,以衡量处方药用植物的效果:结果:草药学家列举了 24 种用于治疗肝炎的植物,其中最常被引用的植物是尼泊尔茜草(Rumex nepalensis)、蔓越桔(Vangueria apiculata)和茄属(Solanum incanum)。治疗方法通常是将其捣碎或研成粉末,加水混合后口服。有 42 人被中医诊断为肝炎患者并接受了治疗,其中有 8 人 HBsAg 阳性,但在抗-HCV ELISA 检测中无阳性结果。在对 HBsAg 阳性者进行病毒载量评估的第三个月和第六个月,观察到有三人在接受常用植物的不同组合治疗后,血清 HBV-DNA 得到抑制:结论:在这项研究中,传统医者使用各种植物治疗肝炎。结论:在这项研究中,传统医学家使用了多种植物治疗肝炎。在使用这些常被引用的、最受青睐的植物的混合物治疗的三名 NAT 阳性患者中,检测到了 HBV DNA 抑制活性。这表明这些植物具有抗病毒特性,可作为更多药理学研究的基础,以寻找新的抗病毒药物。
{"title":"Medicinal Plants in Treating Hepatitis B Among Communities of Central Region of Ethiopia.","authors":"Gizachew Beykaso, Tilahun Teklehaymanot, Andargachew Mulu, Nega Berhe, Dawit Hailu Alemayehu, Mirutse Giday","doi":"10.2147/HMER.S440351","DOIUrl":"10.2147/HMER.S440351","url":null,"abstract":"<p><strong>Purpose: </strong>In Ethiopia, most people rely heavily on traditional therapeutic plants that have been used for years. The practice of traditional medicines use to treat hepatitis is currently gaining popularity due to the limited availability and affordability of modern drugs. The aim of this study was, therefore, to assess the traditional medicinal plants use to treat viral hepatitis among communities of Central region of Ethiopia.</p><p><strong>Methods: </strong>Data was collected from November 2018 to December 2021 in Central Ethiopia. An open-ended semi-structured interview was used among purposively selected herbalists, traditional medicine entrepreneurs, village heads, and patients visiting traditional healers for hepatitis treatments. A 5 mL blood sample was collected from patients who visited a traditional healers' clinic for hepatitis treatment and tested for HBsAg and HCV-antibody by using ELISA. Among HBsAg-positives, further nucleic acid test for HBV-DNA load was assessed to measure the effects of prescribed medicinal plants.</p><p><strong>Results: </strong>Herbalists cited 24 plants that were used for hepatitis treatment; of which <i>Rumex nepalensis, Vangueria apiculata</i>, and <i>Solanum incanum</i> were the most frequently cited plants. Remedies were commonly prepared by crushing or powdering, mixing them with water, and taken orally. Forty-two individuals were diagnosed and treated as hepatitis patients by herbalists, of which eight of them were HBsAg-positive but no positives for anti-HCV ELISA. At the third and sixth months of viral load assessment among HBsAg-positive, serum HBV-DNA suppression was observed in three individuals treated with different combinations of frequently cited plants.</p><p><strong>Conclusion: </strong>In this study, traditional healers used various plants to treat hepatitis. HBV-DNA suppressive activity was detected in three NAT-positive individuals who were treated by using a mixture of these frequently cited and highest preference-ranked plants. This suggests that these plants have antiviral properties and serve as a basis for more pharmacological research in the quest for new antiviral agents.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"265-277"},"PeriodicalIF":2.1,"publicationDate":"2023-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10759923/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139086565","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma. 二硫化相关lncRNA是预测肝细胞癌患者免疫反应和预后的潜在生物标记物
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-27 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S435726
Qian Wei, Yu-Chao Hou, Fei-Fei Mao, Jin-Kai Feng, Xu Wang, Shu-Qun Cheng

Purpose: Hepatocellular carcinoma (HCC) is a prevalent form of cancer that is distributed globally. Disulfidptosis, characterized by the fragility of the actin cytoskeleton, represents a distinct type of cell death and holds promise for novel cancer therapies. Nevertheless, the connection among disulfidptosis-associated long non-coding RNAs (lncRNAs) and HCC is still unexplored. This study uses an in silico approach to provide the novel biomarkers of disulfidptosis-associated lncRNAs for predicting the immune response and prognosis with HCC.

Methods: In order to address this gap, we integrated transcriptomic data of HCC from The Cancer Genome Atlas (TCGA) and identified genes that exhibit differential expression with disulfidptosis and lncRNAs. Through co-expression analysis, we identified disulfidptosis-related lncRNAs. Afterwards, by employing univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO), a model for disulfidptosis-associated lncRNA was constructed. The risk model underwent assessment through the utilization of diverse analytical methodologies, including functional enrichment annotation, Kaplan-Meier analysis, principal component analysis (PCA), immune infiltration and immune status analysis, as well as tumor mutation analysis. Furthermore, we discussed the implications of the model in predicting drug sensitivity.

Results: Our study culminated in the construction of a disulfidptosis-related lncRNA model comprising four prognostic disulfidptosis-related lncRNAs (ACYTOR, NRAV, AL080248.1, and AC069307.1). This model demonstrates exceptional diagnostic value for HCC patients and holds practical implications for guiding clinicians in personalizing immunotherapy and drug selection based on individual variations.

Conclusion: In summary, our research introduces a novel predictive tool utilizing disulfidptosis-related lncRNAs, offering potential guidance for the therapeutic management of HCC.

目的:肝细胞癌(HCC)是一种流行于全球的癌症。以肌动蛋白细胞骨架脆弱为特征的二硫化血症是一种独特的细胞死亡类型,有望成为新型癌症疗法。然而,与二硫化相关的长非编码 RNA(lncRNA)与 HCC 之间的联系仍有待探索。本研究采用一种硅学方法提供了二硫化相关lncRNAs的新型生物标志物,用于预测HCC的免疫反应和预后:为了填补这一空白,我们整合了癌症基因组图谱(The Cancer Genome Atlas,TCGA)中的HCC转录组数据,并确定了与二硫化硫和lncRNAs表现出差异表达的基因。通过共表达分析,我们发现了与二硫化硫相关的 lncRNA。随后,通过单变量Cox回归分析和最小绝对收缩与选择算子(LASSO),构建了二硫化血症相关lncRNA的模型。该风险模型通过多种分析方法进行了评估,包括功能富集注释、Kaplan-Meier分析、主成分分析(PCA)、免疫浸润和免疫状态分析以及肿瘤突变分析。此外,我们还讨论了该模型在预测药物敏感性方面的意义:我们的研究最终构建了一个二硫化相关lncRNA模型,该模型由四个预后性二硫化相关lncRNA(ACYTOR、NRAV、AL080248.1和AC069307.1)组成。该模型对 HCC 患者具有卓越的诊断价值,对指导临床医生根据个体差异进行个性化免疫疗法和药物选择具有实际意义:总之,我们的研究介绍了一种利用二硫化相关 lncRNA 的新型预测工具,为 HCC 的治疗管理提供了潜在的指导。
{"title":"Disulfidptosis-Associated lncRNAs are Potential Biomarkers for Predicting Immune Response and Prognosis Within Individuals Diagnosed with Hepatocellular Carcinoma.","authors":"Qian Wei, Yu-Chao Hou, Fei-Fei Mao, Jin-Kai Feng, Xu Wang, Shu-Qun Cheng","doi":"10.2147/HMER.S435726","DOIUrl":"10.2147/HMER.S435726","url":null,"abstract":"<p><strong>Purpose: </strong>Hepatocellular carcinoma (HCC) is a prevalent form of cancer that is distributed globally. Disulfidptosis, characterized by the fragility of the actin cytoskeleton, represents a distinct type of cell death and holds promise for novel cancer therapies. Nevertheless, the connection among disulfidptosis-associated long non-coding RNAs (lncRNAs) and HCC is still unexplored. This study uses an in silico approach to provide the novel biomarkers of disulfidptosis-associated lncRNAs for predicting the immune response and prognosis with HCC.</p><p><strong>Methods: </strong>In order to address this gap, we integrated transcriptomic data of HCC from The Cancer Genome Atlas (TCGA) and identified genes that exhibit differential expression with disulfidptosis and lncRNAs. Through co-expression analysis, we identified disulfidptosis-related lncRNAs. Afterwards, by employing univariate Cox regression analysis and the least absolute shrinkage and selection operator (LASSO), a model for disulfidptosis-associated lncRNA was constructed. The risk model underwent assessment through the utilization of diverse analytical methodologies, including functional enrichment annotation, Kaplan-Meier analysis, principal component analysis (PCA), immune infiltration and immune status analysis, as well as tumor mutation analysis. Furthermore, we discussed the implications of the model in predicting drug sensitivity.</p><p><strong>Results: </strong>Our study culminated in the construction of a disulfidptosis-related lncRNA model comprising four prognostic disulfidptosis-related lncRNAs (ACYTOR, NRAV, AL080248.1, and AC069307.1). This model demonstrates exceptional diagnostic value for HCC patients and holds practical implications for guiding clinicians in personalizing immunotherapy and drug selection based on individual variations.</p><p><strong>Conclusion: </strong>In summary, our research introduces a novel predictive tool utilizing disulfidptosis-related lncRNAs, offering potential guidance for the therapeutic management of HCC.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"249-264"},"PeriodicalIF":2.1,"publicationDate":"2023-12-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10757809/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139073868","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Epidemiology of Hepatitis B in Saudi Arabia from 2006 to 2021. 2006 至 2021 年沙特阿拉伯乙型肝炎流行病学。
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-21 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S438099
Ibrahim G Alghamdi, Rahaf M Alghamdi, Mohamed S Alghamdi, Atheer M Alghamdi, Murad I Alghamdi, Ziyad I Alghamdi, Khalil S Alghamdi

Background: This study describes the epidemiological pattern of acute hepatitis B virus (HBV) infection in Saudi Arabia from 2006 to 2021. It explores case frequency and the crude incidence rate (CIR) by year of diagnosis, age group, region, gender, and nationality of patients.

Methods: Retrospective data on acute hepatitis B cases diagnosed across 20 regions of Saudi Arabia during January 2006 to December 2021 were obtained from the Saudi Ministry of Health's Statistical Yearbook. Statistical analyses were conducted using SPSS version 20.0, employing both parametric and non-parametric tests.

Results: The highest CIR was reported in the regions of Qunfudah, Jeddah, Tabuk, and Taif (28.6, 25.2, 25.1, and 23.4 per 100,000 people). In contrast, the lowest CIR was documented in the regions of Hail, Qurayyat, Jouf, and Hafr AL-Baten (3.6, 3.5, 2.9, and 1.2 per 100,000 people). Incidence rates were notably elevated in those aged 45 years and above (30.6 per 100,000 individuals), followed by the 15-44 age group (14.2 per 100,000 individuals), and were lowest in children aged 0-14 years (0.8 per 100,000 individuals). Regarding gender differences, HBV infection rates were 1.4 times higher in Saudi males than females and 2.2 times higher in non-Saudi males compared to females. Overall, Saudi nationals had a 4.2 times higher HBV infection rate than non-Saudis during the study period.

Conclusion: This study highlights diverse acute Hepatitis B infection rates across Saudi regions, with higher rates in Qunfudah, Jeddah, Tabuk, and Taif, and lower rates in Hail, Qurayyat, Jouf, and Hafr AL-Baten. Predominance among ages 45+, followed by 15-44, and lowest in 0-14 age groups was observed. Gender variations showed notably higher rates in Saudi and non-Saudi males. The notably higher prevalence among Saudi nationals implies key considerations for public health strategies.

背景:本研究描述了 2006 年至 2021 年沙特阿拉伯急性乙型肝炎病毒(HBV)感染的流行病学模式。研究探讨了按诊断年份、年龄组、地区、性别和患者国籍分列的病例频率和粗发病率(CIR):从沙特卫生部的《统计年鉴》中获取了 2006 年 1 月至 2021 年 12 月期间沙特阿拉伯 20 个地区诊断出的急性乙型肝炎病例的回顾性数据。使用 SPSS 20.0 版进行统计分析,采用参数和非参数检验:据报告,群福达、吉达、塔布克和塔伊夫地区的 CIR 最高(每 10 万人分别为 28.6、25.2、25.1 和 23.4)。相比之下,海尔、古莱雅特、朱夫和哈夫尔-巴滕地区的 CIR 最低(每 10 万人中分别为 3.6、3.5、2.9 和 1.2)。45 岁及以上人群的发病率明显较高(每 10 万人中有 30.6 人),其次是 15-44 岁年龄组(每 10 万人中有 14.2 人),而 0-14 岁儿童的发病率最低(每 10 万人中有 0.8 人)。在性别差异方面,沙特男性的 HBV 感染率是女性的 1.4 倍,非沙特男性的感染率是女性的 2.2 倍。总体而言,在研究期间,沙特人的 HBV 感染率是非沙特人的 4.2 倍:这项研究凸显了沙特各地区不同的急性乙型肝炎感染率,其中群福达、吉达、塔布克和塔伊夫的感染率较高,而海尔、古莱雅特、朱夫和哈夫尔-巴滕的感染率较低。据观察,45 岁以上年龄组发病率最高,其次是 15-44 岁年龄组,0-14 岁年龄组发病率最低。性别差异显示,沙特男性和非沙特男性的患病率明显较高。沙特国民的发病率明显较高,这意味着公共卫生战略需要重点考虑。
{"title":"Epidemiology of Hepatitis B in Saudi Arabia from 2006 to 2021.","authors":"Ibrahim G Alghamdi, Rahaf M Alghamdi, Mohamed S Alghamdi, Atheer M Alghamdi, Murad I Alghamdi, Ziyad I Alghamdi, Khalil S Alghamdi","doi":"10.2147/HMER.S438099","DOIUrl":"10.2147/HMER.S438099","url":null,"abstract":"<p><strong>Background: </strong>This study describes the epidemiological pattern of acute hepatitis B virus (HBV) infection in Saudi Arabia from 2006 to 2021. It explores case frequency and the crude incidence rate (CIR) by year of diagnosis, age group, region, gender, and nationality of patients.</p><p><strong>Methods: </strong>Retrospective data on acute hepatitis B cases diagnosed across 20 regions of Saudi Arabia during January 2006 to December 2021 were obtained from the Saudi Ministry of Health's Statistical Yearbook. Statistical analyses were conducted using SPSS version 20.0, employing both parametric and non-parametric tests.</p><p><strong>Results: </strong>The highest CIR was reported in the regions of Qunfudah, Jeddah, Tabuk, and Taif (28.6, 25.2, 25.1, and 23.4 per 100,000 people). In contrast, the lowest CIR was documented in the regions of Hail, Qurayyat, Jouf, and Hafr AL-Baten (3.6, 3.5, 2.9, and 1.2 per 100,000 people). Incidence rates were notably elevated in those aged 45 years and above (30.6 per 100,000 individuals), followed by the 15-44 age group (14.2 per 100,000 individuals), and were lowest in children aged 0-14 years (0.8 per 100,000 individuals). Regarding gender differences, HBV infection rates were 1.4 times higher in Saudi males than females and 2.2 times higher in non-Saudi males compared to females. Overall, Saudi nationals had a 4.2 times higher HBV infection rate than non-Saudis during the study period.</p><p><strong>Conclusion: </strong>This study highlights diverse acute Hepatitis B infection rates across Saudi regions, with higher rates in Qunfudah, Jeddah, Tabuk, and Taif, and lower rates in Hail, Qurayyat, Jouf, and Hafr AL-Baten. Predominance among ages 45+, followed by 15-44, and lowest in 0-14 age groups was observed. Gender variations showed notably higher rates in Saudi and non-Saudi males. The notably higher prevalence among Saudi nationals implies key considerations for public health strategies.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"233-247"},"PeriodicalIF":2.1,"publicationDate":"2023-12-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10749576/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139037604","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analysis of SARS-CoV-2 Variant-Specific Serum Antibody Post-Vaccination Utilizing Immortalized Human Hepatocyte-Like Cells (HLC) to Assess Development of Immunity 利用永久化的类人肝细胞 (HLC) 分析接种后的 SARS-CoV-2 变体特异性血清抗体,以评估免疫力的发展情况
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-01 DOI: 10.2147/HMER.S431327
Daniel Collins, Clifford Steer
Background Our previous studies demonstrated that SARS-CoV-2 spike protein could bind to primary hepatocytes and immortalized Hepatocyte-like cells (HLC) via the asialoglycoprotein receptor-1 (ASGR-1). The binding of biotinylated spike protein could be inhibited by Spike-neutralizing monoclonal antibodies, anti-ASGR-1 antibodies and unlabeled spike protein. The cells were unable to bind Spike S1 and Spike S1 was incapable of blocking labeled Spike protein, suggesting that the Receptor Binding Domain (RBD) was not involved in the binding event. This study was done to investigate the utility of these cells and immortalized alveolar type 2-like (AT-2) cells in studying the development of variant-specific antibodies post-vaccination. Methods Serum was collected from 10 individuals pre- and post-vaccination with the J&J, Moderna or Pfizer vaccines. The serum samples were quantified for variant-specific antibodies in a flow cytometry-based immunofluorescent assay utilizing beads coated with biotinylated variant spike proteins. Inhibition of spike protein binding to HLC and AT-2 cells by donor serum was analyzed by immunofluorescent confocal analysis. Results All variant spike proteins bound to HLC and AT-2 cells. Post-vaccination serum samples demonstrated increases of SARS-CoV-2 antibody levels from 2 weeks to 2.5 months post-vaccination with associated increased spike-blocking capacity. It was also demonstrated that vaccination with all the available vaccines stimulated antibodies that inhibited binding of all the available variant spike proteins to both HLC and AT-2 cells. Conclusion HLC, along with AT-2 cells, provides a useful platform to study the development of neutralizing antibodies post-vaccination. Vaccination with the 3 available vaccines all elicited neutralizing serum antibodies that inhibited binding of each of the variant spike proteins to both AT-2 and HLC cells. This study suggests that inhibition of spike binding to target cells may be a more useful technique to assess immunity than gross quantitation of antibody.
我们之前的研究表明,SARS-CoV-2刺突蛋白可以通过asialglycoprotein receptor-1 (ASGR-1)与原代肝细胞和永生化肝细胞样细胞(HLC)结合。生物素化刺突蛋白的结合可被刺突中和单克隆抗体、抗asgr -1抗体和未标记的刺突蛋白抑制。细胞无法与Spike S1结合,Spike S1无法阻断标记的Spike蛋白,表明受体结合域(Receptor Binding Domain, RBD)未参与结合事件。本研究旨在探讨这些细胞和永活肺泡2型样(AT-2)细胞在研究疫苗接种后变异体特异性抗体发展中的作用。方法采集10例接种强生、Moderna和辉瑞三种疫苗前后的血清。在基于流式细胞术的免疫荧光分析中,利用涂有生物素化变异刺突蛋白的微珠,对血清样本进行变异特异性抗体定量。免疫荧光共聚焦分析供体血清对HLC和AT-2细胞的抑制作用。结果所有变异刺突蛋白均与HLC和AT-2细胞结合。疫苗接种后血清样本显示,在疫苗接种后2周至2.5个月期间,SARS-CoV-2抗体水平升高,并伴有相关的spike阻断能力增强。研究还表明,接种所有可用的疫苗可刺激抗体,抑制所有可用的变异刺突蛋白与hcc和AT-2细胞的结合。结论hplc和AT-2细胞为研究疫苗接种后中和抗体的发展提供了一个有用的平台。接种3种可用疫苗均可引起中和性血清抗体,抑制每种变异刺突蛋白与AT-2和hcc细胞的结合。这项研究表明抑制刺突与靶细胞的结合可能是一种比抗体总量更有用的评估免疫的技术。
{"title":"Analysis of SARS-CoV-2 Variant-Specific Serum Antibody Post-Vaccination Utilizing Immortalized Human Hepatocyte-Like Cells (HLC) to Assess Development of Immunity","authors":"Daniel Collins, Clifford Steer","doi":"10.2147/HMER.S431327","DOIUrl":"https://doi.org/10.2147/HMER.S431327","url":null,"abstract":"Background Our previous studies demonstrated that SARS-CoV-2 spike protein could bind to primary hepatocytes and immortalized Hepatocyte-like cells (HLC) via the asialoglycoprotein receptor-1 (ASGR-1). The binding of biotinylated spike protein could be inhibited by Spike-neutralizing monoclonal antibodies, anti-ASGR-1 antibodies and unlabeled spike protein. The cells were unable to bind Spike S1 and Spike S1 was incapable of blocking labeled Spike protein, suggesting that the Receptor Binding Domain (RBD) was not involved in the binding event. This study was done to investigate the utility of these cells and immortalized alveolar type 2-like (AT-2) cells in studying the development of variant-specific antibodies post-vaccination. Methods Serum was collected from 10 individuals pre- and post-vaccination with the J&J, Moderna or Pfizer vaccines. The serum samples were quantified for variant-specific antibodies in a flow cytometry-based immunofluorescent assay utilizing beads coated with biotinylated variant spike proteins. Inhibition of spike protein binding to HLC and AT-2 cells by donor serum was analyzed by immunofluorescent confocal analysis. Results All variant spike proteins bound to HLC and AT-2 cells. Post-vaccination serum samples demonstrated increases of SARS-CoV-2 antibody levels from 2 weeks to 2.5 months post-vaccination with associated increased spike-blocking capacity. It was also demonstrated that vaccination with all the available vaccines stimulated antibodies that inhibited binding of all the available variant spike proteins to both HLC and AT-2 cells. Conclusion HLC, along with AT-2 cells, provides a useful platform to study the development of neutralizing antibodies post-vaccination. Vaccination with the 3 available vaccines all elicited neutralizing serum antibodies that inhibited binding of each of the variant spike proteins to both AT-2 and HLC cells. This study suggests that inhibition of spike binding to target cells may be a more useful technique to assess immunity than gross quantitation of antibody.","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":" 10","pages":"221 - 231"},"PeriodicalIF":2.1,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138610289","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
COVID-19 and the Liver: A Complex and Evolving Picture. 2019冠状病毒病与肝脏:一幅复杂而不断演变的图景。
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-11-07 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S384172
Simon D Taylor-Robinson, Marsha Y Morgan

Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily attacks the respiratory system, other organs, such as the liver, are also affected. In this overview, the effects of SARS-CoV-2 infection on the liver in both healthy people and in those with pre-existing liver disease are documented; the relationship between coronavirus disease 19 (COVID-19) vaccination and liver injury is examined; the mechanism of SARS-CoV-2-associated liver injury is explored; and the long-term consequences of COVID-19 are delineated, both in people with and without pre-existing liver disease.

虽然严重急性呼吸综合征冠状病毒2 (SARS-CoV-2)主要攻击呼吸系统,但肝脏等其他器官也会受到影响。在本综述中,记录了SARS-CoV-2感染对健康人群和已有肝病患者肝脏的影响;研究冠状病毒病(COVID-19)疫苗接种与肝损伤的关系;探索sars - cov -2相关肝损伤机制;并描述了COVID-19对患有和不患有肝脏疾病的人的长期后果。
{"title":"COVID-19 and the Liver: A Complex and Evolving Picture.","authors":"Simon D Taylor-Robinson, Marsha Y Morgan","doi":"10.2147/HMER.S384172","DOIUrl":"10.2147/HMER.S384172","url":null,"abstract":"<p><p>Although the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) primarily attacks the respiratory system, other organs, such as the liver, are also affected. In this overview, the effects of SARS-CoV-2 infection on the liver in both healthy people and in those with pre-existing liver disease are documented; the relationship between coronavirus disease 19 (COVID-19) vaccination and liver injury is examined; the mechanism of SARS-CoV-2-associated liver injury is explored; and the long-term consequences of COVID-19 are delineated, both in people with and without pre-existing liver disease.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"209-220"},"PeriodicalIF":2.1,"publicationDate":"2023-11-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10641025/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"107591067","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Confounders of Serum Phosphatidylethanol: Role of Red Blood Cell Turnover and Cirrhosis. 血清磷脂酰乙醇:红细胞周转和肝硬化的作用。
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-11-01 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S420732
Marc Bartel, Vanessa Hofmann, Shijin Wang, Johannes Mueller, Tom R Sundermann, Sebastian Mueller

Purpose: Ethyl glucuronide (EtG), ethyl sulfate (EtS) and phosphatidylethanol (PEth) are considered specific direct biomarkers for detecting alcohol consumption. However, PEth, which is produced in red blood cells (RBC), varies considerably between patients for unknown reasons. We here studied various confounders of PEth elimination including fibrosis after alcohol withdrawal.

Patients and methods: EtG, EtS and PEth together with routine laboratory and clinical parameters were studied in 100 Caucasian heavy drinkers prior and after alcohol detoxification. In addition, fibrosis stage and degree of steatosis were assessed by transient elastography (Fibroscan, Echosens, Paris).

Results: All three biomarkers were highly correlated (0.61-0.72) with initial serum alcohol levels, but only PEth correlated with daily alcohol consumption. After alcohol withdrawal, PEth significantly decreased within 6.1 days from 1708 to 810 ng/mL (half-life varied from 1.6 to 15.2 days). Both levels of serum alcohol but also EtG and EtS were higher in patients with liver cirrhosis as compared to patients without fibrosis despite comparable alcohol consumption suggesting a decreased alcohol elimination in patients with cirrhosis. PEth was also elevated in cirrhosis but not significantly. In contrast, PEth elimination rate was significantly higher in patients with enhanced RBC turnover and signs of alcohol-mediated hemolytic anemia with elevated ferritin, LDH and increased mean corpuscular volume (MCV).

Conclusion: We here demonstrate that alcohol elimination is decreased in patients with liver cirrhosis. In patients with cirrhosis, PEth levels are both affected in opposite directions by enhanced red blood cell turnover and elevated alcohol levels. Our data have important implications for the use and interpretation of PEth in the clinical setting.

目的:葡萄糖醛酸乙酯(EtG)、硫酸乙酯(EtS)和磷脂酰乙醇(PEth)被认为是检测饮酒量的特异性直接生物标志物。然而,由于未知原因,红细胞(RBC)中产生的PEth在患者之间差异很大。我们在这里研究了PEth消除的各种混杂因素,包括酒精戒断后的纤维化。患者和方法:对100名高加索人重度饮酒者在酒精解毒前后的EtG、EtS和PEth以及常规实验室和临床参数进行了研究。此外,通过瞬态弹性成像(Fibroscan,Echosens,Paris)评估纤维化分期和脂肪变性程度。结果:所有三种生物标志物与初始血清酒精水平高度相关(0.61-0.72),但只有PEth与每日饮酒量相关。停酒后,PEth在6.1天内从1708 ng/mL显著降低至810 ng/mL(半衰期从1.6天至15.2天不等)。与没有纤维化的患者相比,肝硬化患者的血清酒精水平以及EtG和EtS水平都更高,尽管饮酒量相当,表明肝硬化患者的酒精消除减少。肝硬化患者PEth也升高,但不显著。相反,红细胞周转率升高、伴有铁蛋白、LDH升高和平均红细胞体积(MCV)增加的酒精介导的溶血性贫血症状的患者,PEth清除率显著较高。结论:我们证明肝硬化患者的酒精清除率降低。在肝硬化患者中,PEth水平受到红细胞周转增强和酒精水平升高的相反影响。我们的数据对临床环境中PEth的使用和解释具有重要意义。
{"title":"Confounders of Serum Phosphatidylethanol: Role of Red Blood Cell Turnover and Cirrhosis.","authors":"Marc Bartel, Vanessa Hofmann, Shijin Wang, Johannes Mueller, Tom R Sundermann, Sebastian Mueller","doi":"10.2147/HMER.S420732","DOIUrl":"https://doi.org/10.2147/HMER.S420732","url":null,"abstract":"<p><strong>Purpose: </strong>Ethyl glucuronide (EtG), ethyl sulfate (EtS) and phosphatidylethanol (PEth) are considered specific direct biomarkers for detecting alcohol consumption. However, PEth, which is produced in red blood cells (RBC), varies considerably between patients for unknown reasons. We here studied various confounders of PEth elimination including fibrosis after alcohol withdrawal.</p><p><strong>Patients and methods: </strong>EtG, EtS and PEth together with routine laboratory and clinical parameters were studied in 100 Caucasian heavy drinkers prior and after alcohol detoxification. In addition, fibrosis stage and degree of steatosis were assessed by transient elastography (Fibroscan, Echosens, Paris).</p><p><strong>Results: </strong>All three biomarkers were highly correlated (0.61-0.72) with initial serum alcohol levels, but only PEth correlated with daily alcohol consumption. After alcohol withdrawal, PEth significantly decreased within 6.1 days from 1708 to 810 ng/mL (half-life varied from 1.6 to 15.2 days). Both levels of serum alcohol but also EtG and EtS were higher in patients with liver cirrhosis as compared to patients without fibrosis despite comparable alcohol consumption suggesting a decreased alcohol elimination in patients with cirrhosis. PEth was also elevated in cirrhosis but not significantly. In contrast, PEth elimination rate was significantly higher in patients with enhanced RBC turnover and signs of alcohol-mediated hemolytic anemia with elevated ferritin, LDH and increased mean corpuscular volume (MCV).</p><p><strong>Conclusion: </strong>We here demonstrate that alcohol elimination is decreased in patients with liver cirrhosis. In patients with cirrhosis, PEth levels are both affected in opposite directions by enhanced red blood cell turnover and elevated alcohol levels. Our data have important implications for the use and interpretation of PEth in the clinical setting.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"195-208"},"PeriodicalIF":2.1,"publicationDate":"2023-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10625785/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71480921","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure? 严重急性呼吸系统综合征冠状病毒2型感染后肝功能障碍患者的预后:我们应该测量什么?
IF 2.6 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-12 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S371507
Nimy John, Brittney Ibrahim, Mark Ebaid, Sammy Saab

Aim: Since 2019, the COVID-19 pandemic wreaked havoc all over the world. Early in the course of the pandemic, multiple hepatic manifestations of COVID-19 were noted. We aim to categorize hepatic dysfunction and its outcome in COVID-19 infection.

Methods: This is a review article based on a literature search in PubMed and Medline databases for articles detailing short-term and long-term outcomes of COVID-19 related liver dysfunction.

Results: The most common hepatic manifestation of COVID-19 was aspartate amino transferase (AST) predominant transaminase elevation. Transaminases improve once the COVID-19 infection resolves. In addition, COVID-19 cholangiopathy, autoimmune hepatitis associated COVID-19, and splanchnic venous thrombosis triggered by COVID-19 are other manifestations. Patients with preexisting liver disease, especially those with cirrhosis, have poor prognosis with COVID-19 infections compared to the general population. Elevations in liver tests were associated with severe COVID-19 infections. Patients with chronic liver disease have a higher risk of morbidity and mortality from COVID-19 infection. Among patients with chronic liver disease, decompensated liver cirrhosis, hepatocellular carcinoma and alcohol-associated liver disease were associated with an increased risk of severity and mortality from COVID-19 infection. Interactions between antiviral therapy for COVID-19 and hepatitis B/hepatitis C medications must be considered in patients with chronic viral hepatitis and COVID-19 infection. COVID-19 vaccination-related hepatic dysfunction has been reported.

Conclusion: COVID-19 is here to stay. Hepatic dysfunction in COVID-19 signals severe COVID-19 infections. Patients with chronic liver disease have higher mortality from COVID-19 than general population. It is important to remember the lessons learned throughout the covid pandemic to take care of patients with COVID-19 now and in the future. Further studies are needed to document long-term outcomes in patients with COVID-19 who developed hepatic dysfunction.

目标:自2019年以来,新冠肺炎疫情在世界各地肆虐。在大流行的早期,注意到新冠肺炎的多种肝脏表现。我们的目的是对新冠肺炎感染的肝功能障碍及其结果进行分类。方法:这是一篇综述文章,基于PubMed和Medline数据库中的文献检索,详细介绍了新冠肺炎相关肝功能障碍的短期和长期结果。结果:新冠肺炎最常见的肝脏表现是天冬氨酸氨基转移酶(AST)为主的转氨酶升高。一旦新冠肺炎感染消退,转氨酶就会改善。此外,新冠肺炎胆道病、自身免疫性肝炎相关的新冠肺炎和新冠肺炎引发的内脏静脉血栓形成也是其他表现。与普通人群相比,已有肝病的患者,尤其是肝硬化患者,感染新冠肺炎的预后较差。肝脏检查的升高与严重的新冠肺炎感染有关。慢性肝病患者感染新冠肺炎的发病率和死亡率较高。在慢性肝病患者中,失代偿性肝硬化、肝细胞癌和酒精相关性肝病与新冠肺炎感染的严重程度和死亡率增加相关。在慢性病毒性肝炎和新冠肺炎感染患者中,必须考虑新冠肺炎抗病毒治疗与乙型肝炎/丙型肝炎药物之间的相互作用。新冠肺炎疫苗接种相关的肝功能障碍已有报道。结论:新冠肺炎将持续存在。新冠肺炎肝功能不全是严重新冠肺炎感染的信号。慢性肝病患者死于新冠肺炎的死亡率高于普通人群。重要的是要记住在新冠肺炎大流行期间吸取的教训,以便现在和将来照顾新冠肺炎患者。需要进一步的研究来记录发生肝功能障碍的新冠肺炎患者的长期结果。
{"title":"Outcomes in Patients with Liver Dysfunction Post SARS-CoV-2 Infection: What Should We Measure?","authors":"Nimy John, Brittney Ibrahim, Mark Ebaid, Sammy Saab","doi":"10.2147/HMER.S371507","DOIUrl":"10.2147/HMER.S371507","url":null,"abstract":"<p><strong>Aim: </strong>Since 2019, the COVID-19 pandemic wreaked havoc all over the world. Early in the course of the pandemic, multiple hepatic manifestations of COVID-19 were noted. We aim to categorize hepatic dysfunction and its outcome in COVID-19 infection.</p><p><strong>Methods: </strong>This is a review article based on a literature search in PubMed and Medline databases for articles detailing short-term and long-term outcomes of COVID-19 related liver dysfunction.</p><p><strong>Results: </strong>The most common hepatic manifestation of COVID-19 was aspartate amino transferase (AST) predominant transaminase elevation. Transaminases improve once the COVID-19 infection resolves. In addition, COVID-19 cholangiopathy, autoimmune hepatitis associated COVID-19, and splanchnic venous thrombosis triggered by COVID-19 are other manifestations. Patients with preexisting liver disease, especially those with cirrhosis, have poor prognosis with COVID-19 infections compared to the general population. Elevations in liver tests were associated with severe COVID-19 infections. Patients with chronic liver disease have a higher risk of morbidity and mortality from COVID-19 infection. Among patients with chronic liver disease, decompensated liver cirrhosis, hepatocellular carcinoma and alcohol-associated liver disease were associated with an increased risk of severity and mortality from COVID-19 infection. Interactions between antiviral therapy for COVID-19 and hepatitis B/hepatitis C medications must be considered in patients with chronic viral hepatitis and COVID-19 infection. COVID-19 vaccination-related hepatic dysfunction has been reported.</p><p><strong>Conclusion: </strong>COVID-19 is here to stay. Hepatic dysfunction in COVID-19 signals severe COVID-19 infections. Patients with chronic liver disease have higher mortality from COVID-19 than general population. It is important to remember the lessons learned throughout the covid pandemic to take care of patients with COVID-19 now and in the future. Further studies are needed to document long-term outcomes in patients with COVID-19 who developed hepatic dysfunction.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"185-193"},"PeriodicalIF":2.6,"publicationDate":"2023-10-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/b8/39/hmer-15-185.PMC10578169.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41234818","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Integrated Bioinformatic Assay of Genetic Expression Features and Analyses of Traditional Chinese Medicine Specific Constitution Reveal Metabolic Characteristics and Targets in Steatosis of Nonalcoholic Fatty Liver Disease. 基因表达特征的生物信息学综合分析和中药特异性组成分析揭示了非酒精性脂肪肝脂肪变性的代谢特征和靶点。
IF 2.1 Q2 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-10-06 eCollection Date: 2023-01-01 DOI: 10.2147/HMER.S428161
Chunping Qiao, Chengying Gu, Song Wen, Yanju He, Sheng Yang, Xinge Feng, Yipeng Zeng

Purpose: In this study, our primary aim is to analyze the genetic expression feature and analyze specific Traditional Chinese medicine (TCM) constitution distribution in non-alcoholic fatty liver disease (NAFLD) and reveal the metabolic characteristic of NAFLD.

Materials and methods: For revealing genetic features, we obtained the gene expression data from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). The genetic data on NAFLD were analyzed by identifying differentially expressed genes (DEGs), associated pathways, co-expressed genetic networks, and gene set enrichment function. Concurrently, we assessed specific constitution distributions among local NAFLD patients through established TCM constitution models and determined the independent variable, including specific constitution to the NAFLD via the regression analyses.

Results: The analyses on GEO datasets showed that simple steatosis in NAFLD is strongly associated with HOMA-insulin resistance (HOMA-IR). Analyses of GEO datasets revealed significantly altered genetic expression profiles between NAFLD and normal populations. For TCM constitution analyses, we demonstrated a decline in yin-yang harmony (YYH) and yang-asthenia (YAAC) constitution, whereas there was an increase in qi-stagnation (QSC) and phlegm-dampness (PDC) in NAFLD. The binary logistic regression analysis indicated that besides other metabolic parameters, YYH, qi asthenia (QAC), YYAC, and yin-asthenia (YAC) were the independent variables of NAFLD, while YAC was the independent variables of T2D. The multilinear regression analyses suggested that NAFLD, DM, BMI, waist, TC, TG, hypertension, ALT, AST, and YAC were the significant determinators of the FPG.

Conclusion: This study presents a relatively comprehensive metabolic profile in steatosis of NAFLD, revealed by significant genetic expression feature alterations and different TCM constitution distribution in NAFLD. Through this method, the study intends to associate the genetic feature with the phenotype of TCM constitution. The results could be applied to assist integrative medicine research in exploring the appropriate personalized approaches for NAFLD.

目的:本研究的主要目的是分析非酒精性脂肪性肝病(NAFLD)的遗传表达特征,分析特定的中医体质分布,揭示NAFLD的代谢特征。材料和方法:为了揭示遗传特征,我们从国家生物技术信息中心(NCBI)的基因表达综合数据库(GEO)中获得了基因表达数据。通过鉴定差异表达基因(DEGs)、相关途径、共表达遗传网络和基因集富集功能来分析NAFLD的遗传数据。同时,我们通过建立的中医体质模型评估了局部NAFLD患者的特定体质分布,并通过回归分析确定了自变量,包括NAFLD的特定体质。结果:对GEO数据集的分析表明,NAFLD中的简单脂肪变性与HOMA胰岛素抵抗(HOMA-IR)密切相关。对GEO数据集的分析显示,NAFLD和正常人群之间的基因表达谱发生了显著变化。在中医体质分析中,我们发现NAFLD的阴阳调和(YYH)和阳虚(YAAC)体质下降,而气滞(QSC)和痰湿(PDC)增加。二元逻辑回归分析表明,除其他代谢参数外,YYH、气虚(QAC)、YYAC和阴虚(YAC)是NAFLD的自变量,YAC是T2D的自变量。多元线性回归分析表明,NAFLD、DM、BMI、腰围、TC、TG、高血压、ALT、AST和YAC是FPG的重要决定因素。结论:本研究提供了一个相对全面的NAFLD脂肪变性代谢谱,通过显著的遗传表达特征改变和NAFLD不同的中医体质分布来揭示。通过这种方法,本研究旨在将遗传特征与中医体质表型联系起来。研究结果可用于协助综合医学研究探索适合NAFLD的个性化方法。
{"title":"The Integrated Bioinformatic Assay of Genetic Expression Features and Analyses of Traditional Chinese Medicine Specific Constitution Reveal Metabolic Characteristics and Targets in Steatosis of Nonalcoholic Fatty Liver Disease.","authors":"Chunping Qiao,&nbsp;Chengying Gu,&nbsp;Song Wen,&nbsp;Yanju He,&nbsp;Sheng Yang,&nbsp;Xinge Feng,&nbsp;Yipeng Zeng","doi":"10.2147/HMER.S428161","DOIUrl":"https://doi.org/10.2147/HMER.S428161","url":null,"abstract":"<p><strong>Purpose: </strong>In this study, our primary aim is to analyze the genetic expression feature and analyze specific Traditional Chinese medicine (TCM) constitution distribution in non-alcoholic fatty liver disease (NAFLD) and reveal the metabolic characteristic of NAFLD.</p><p><strong>Materials and methods: </strong>For revealing genetic features, we obtained the gene expression data from the Gene Expression Omnibus (GEO) database of the National Center for Biotechnology Information (NCBI). The genetic data on NAFLD were analyzed by identifying differentially expressed genes (DEGs), associated pathways, co-expressed genetic networks, and gene set enrichment function. Concurrently, we assessed specific constitution distributions among local NAFLD patients through established TCM constitution models and determined the independent variable, including specific constitution to the NAFLD via the regression analyses.</p><p><strong>Results: </strong>The analyses on GEO datasets showed that simple steatosis in NAFLD is strongly associated with HOMA-insulin resistance (HOMA-IR). Analyses of GEO datasets revealed significantly altered genetic expression profiles between NAFLD and normal populations. For TCM constitution analyses, we demonstrated a decline in yin-yang harmony (YYH) and yang-asthenia (YAAC) constitution, whereas there was an increase in qi-stagnation (QSC) and phlegm-dampness (PDC) in NAFLD. The binary logistic regression analysis indicated that besides other metabolic parameters, YYH, qi asthenia (QAC), YYAC, and yin-asthenia (YAC) were the independent variables of NAFLD, while YAC was the independent variables of T2D. The multilinear regression analyses suggested that NAFLD, DM, BMI, waist, TC, TG, hypertension, ALT, AST, and YAC were the significant determinators of the FPG.</p><p><strong>Conclusion: </strong>This study presents a relatively comprehensive metabolic profile in steatosis of NAFLD, revealed by significant genetic expression feature alterations and different TCM constitution distribution in NAFLD. Through this method, the study intends to associate the genetic feature with the phenotype of TCM constitution. The results could be applied to assist integrative medicine research in exploring the appropriate personalized approaches for NAFLD.</p>","PeriodicalId":12917,"journal":{"name":"Hepatic Medicine : Evidence and Research","volume":"15 ","pages":"165-183"},"PeriodicalIF":2.1,"publicationDate":"2023-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/e8/57/hmer-15-165.PMC10563782.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41199330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepatic Medicine : Evidence and Research
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1